On May 6, 2024, Cellectis S.A., closed the transaction. As the result of the transaction, AstraZeneca PLC, now owns approximately 44% of the share capital and 30% of the voting rights of the company.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,596 GBX | +0.32% | +2.11% | +18.92% |
03:46pm | ASTRAZENECA : Berenberg raises its price target | CF |
01:58pm | AstraZeneca shares outperform, Berenberg raises target | CF |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
12,596 GBX | +0.32% | +2.11% | 248B | ||
2.27 EUR | -3.81% | -6.00% | 255M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.92% | 248B | |
+47.08% | 765B | |
-6.11% | 354B | |
+20.09% | 331B | |
+8.84% | 299B | |
-1.68% | 219B | |
+11.06% | 216B | |
+5.54% | 164B | |
-2.80% | 162B | |
-0.18% | 123B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- Cellectis S.A. announced that it has received $140 million in funding from AstraZeneca PLC